Pancreatic KCa3.1 channels in health and disease
Author:
Soret Benjamin1, Hense Jurek2, Lüdtke Simon2, Thale Insa3, Schwab Albrecht1, Düfer Martina2ORCID
Affiliation:
1. University of Münster, Institute of Physiology II , Robert-Koch-Straße 27b, D-48149 Münster , Germany 2. University of Münster, Institute of Pharmaceutical and Medicinal Chemistry , Department of Pharmacology , Corrensstraße 48, D-48149 Münster , Germany 3. University of Münster, Institute of Pharmaceutical and Medicinal Chemistry , Corrensstraße 48, D-48149 Münster , Germany
Abstract
Abstract
Ion channels play an important role for regulation of the exocrine and the endocrine pancreas. This review focuses on the Ca2+-regulated K+ channel KCa3.1, encoded by the KCNN4 gene, which is present in both parts of the pancreas. In the islets of Langerhans, KCa3.1 channels are involved in the regulation of membrane potential oscillations characterizing nutrient-stimulated islet activity. Channel upregulation is induced by gluco- or lipotoxic conditions and might contribute to micro-inflammation and impaired insulin release in type 2 diabetes mellitus as well as to diabetes-associated renal and vascular complications. In the exocrine pancreas KCa3.1 channels are expressed in acinar and ductal cells. They are thought to play a role for anion secretion during digestion but their physiological role has not been fully elucidated yet. Pancreatic carcinoma, especially pancreatic ductal adenocarcinoma (PDAC), is associated with drastic overexpression of KCa3.1. For pharmacological targeting of KCa3.1 channels, we are discussing the possible benefits KCa3.1 channel inhibitors might provide in the context of diabetes mellitus and pancreatic cancer, respectively. We are also giving a perspective for the use of a fluorescently labeled derivative of the KCa3.1 blocker senicapoc as a tool to monitor channel distribution in pancreatic tissue. In summary, modulating KCa3.1 channel activity is a useful strategy for exo-and endocrine pancreatic disease but further studies are needed to evaluate its clinical suitability.
Funder
Deutsche Forschungsgemeinschaft
Publisher
Walter de Gruyter GmbH
Subject
Clinical Biochemistry,Molecular Biology,Biochemistry
Reference112 articles.
1. Andersen, D.K., Korc, M., Petersen, G.M., Eibl, G., Li, D., Rickels, M.R., Chari, S.T., and Abbruzzese, J.L. (2017). Diabetes, pancreatogenic diabetes, and pancreatic cancer. Diabetes 66: 1103–1110, https://doi.org/10.2337/db16-1477. 2. Apte, M.V., Pirola, R.C., and Wilson, J.S. (2012). Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front. Physiol. 3: 344, https://doi.org/10.3389/fphys.2012.00344. 3. Arnush, M., Heitmeier, M.R., Scarim, A.L., Marino, M.H., Manning, P.T., and Corbett, J.A. (1998). IL-1 produced and released endogenously within human islets inhibits beta cell function. J. Clin. Invest. 102: 516–526, https://doi.org/10.1172/jci844. 4. Ataga, K.I., Smith, W.R., Castro, L.M.de, Swerdlow, P., Saunthararajah, Y., Castro, O., Vichinsky, E., Kutlar, A., Orringer, E.P., Rigdon, G.C., et al.. (2008). Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia. Blood 111: 3991–3997, https://doi.org/10.1182/blood-2007-08-110098. 5. Backx, E., Coolens, K., van den Bossche, J.L., Houbracken, I., Espinet, E., and Rooman, I. (2022). On the origin of pancreatic cancer: molecular tumor subtypes in perspective of exocrine cell plasticity. Cell. Mol. Gastroenterol. Hepatol. 13: 1243–1253, https://doi.org/10.1016/j.jcmgh.2021.11.010.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|